Compare Amgen, Inc. (AMGN) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Open Text Corporation — how do they compare? Amgen, Inc. trades at $356.4 (market cap $196.12B), while Open Text Corporation trades at $23.61 (market cap $5.56B). The key difference: Amgen, Inc. is far larger — about 35.3× Open Text Corporation's market cap, and Open Text Corporation pays the higher dividend (4.78%). Which is the better fit depends on your goals.
| AMGN | OTEX | |
|---|---|---|
Market Cap | $196.12B | $5.56B |
Sector | Health | Technology |
52-Week High | $388.16 | $39.69 |
52-Week Low | $271.18 | $20.01 |
Enterprise Value | $241.41B | $10.72B |
Dividend Yield | 2.77% | 4.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
OTEX trades at $23.01, up 0.17% today, with a bullish technical signal from moving averages and a consensus analyst price target of $29.75 implying 29% upside. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.994 exceeding expectations, and maintains robust profitability with a 73.06% gross margin. Recent developments include a $105 million investment in European AI and cloud expansion and the divestiture of non-core assets.
The outlook is positive given undervalued metrics like a P/E of 11.17 and EV/EBITDA of 6.7, alongside strategic focus on AI and cloud growth. Risks include execution challenges in integrating new investments and competitive pressures in the tech sector. Investor sentiment is cautiously optimistic, supported by analyst upgrades and institutional interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
